Simeprevir and Sofosbuvir Submitted to FDA — Clock Ticking on Boceprevir, Telaprevir, Even Interferon

In his blog HIV and ID Observations, Dr. Paul Sax discusses two new HCV drugs that are currently awaiting FDA approval.

This spring, two drug companies have submitted New Drug Applications to the FDA for drugs to treat chronic hepatitis C infection. Both simeprevir (an NS3/4A protease inhibitor; Janssen Research and Development) and sofosbuvir (a nucleotide analogue; Gilead Sciences) have looked promising in clinical trials to date. In his blog HIV and ID Observations, Dr. Paul Sax notes that, barring unforeseen occurrences that hold up these approvals, better HCV treatment options may be available in less than a year.

Simeprevir and Sofosbuvir Submitted to FDA — Clock Ticking on Boceprevir, Telaprevir, Even Interferon

Topics